Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017

Date: April 3, 2013
Pages: 360
Price:
US$ 4,650.00 US$ 4,090.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NE5571DF3C8EN
Leaflet:

Download PDF Leaflet

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lion’s share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope. Furthermore, the PET market will witness a double digit growth during the forecast period. The therapeutic segment contributes only 10% to the global radiopharmaceuticals market and I-131 has been considered as the gold standard for various oncology treatments in a combined therapy. Global nuclear medicines market is majorly driven by the increasing adoption of PET and SPECT scanners, and rising awareness for radiopharmaceuticals, whereas short half life of isotopes and stringent regulations are the factors that are hindering the growth of radiopharmaceuticals worldwide.

Besides highly preferred isotopes such as Tc-99m and F-18, significant growth is witnessed for Tl-201 and Rb-82 in diagnostic market and Y-90 and Lu-177 in beta therapy radioisotopes market. Exhaustive pipeline analysis reveals that coronary heart disease, Alzheimer’s disease, breast cancer, and bone metastasis will drive the diagnostic radiopharmaceuticals market, whereas lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma will boost the future of therapeutic radiopharmaceuticals. Besides new applications, the potential molecules that are expected to drive the market include Alpharadin (Ra-223), Ga-68, F-18 florbetapir, and F-18 choline. Though Ra-223 application is still under clinical trial, the market is highly optimistic regarding its clinical efficiency in prostate cancer, and bone metastasis.

North America held the largest share in the global radiopharmaceuticals market. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. China, India, Japan, South Korea, Brazil, and South Africa are expected to show a high growth potential amongst the emerging geographies. These countries are influenced by the domestic production of isotopes by reactors and government initiatives.

Apart from upcoming isotopes and their applications, understanding of the interlinked supply chain was imperative for market estimation. Value chain analysis and pipeline analysis have taken care of such business issues to come up with a consolidated market analysis, including the present and future impact of different factors. Demand and supply analysis identifies the potential risk of the interrupted supply of Mo-99 for the Tc-99m production, due to scheduled shutdown of major reactors and the benchmarking trend adopted by leading players to combat such operational difficulties.

The radiopharmaceutical market has been analyzed from both the radiopharmaceuticals processors’ and generator manufacturer’s perspectives. It has been identified that shifting from HEU to LEU is the major strategy in the processors market, while strengthening the supply chain of radiopharmaceuticals is the prime concern for the generator manufacturers.

In addition to the market size and forecast for radioisotopes, the report also covers competitive landscape and key developments of major players, pipeline analysis, investment opportunities, and regulatory affairs for established players as well as new entrants.

Custom Research/Customization details

RADIOPHARMACEUTICALS MARKET

1. PET and SPECT procedural volume (No. of procedures) at regional level and by Isotope
  • Estimation of diagnostic and therapeutic procedures in North America, Europe, Asia, and RoW for 2010, 2011, 2012, and the forecast for 2017
  • Estimation of SPECT, PET, Beta emitters and Brachytherapy procedures in North America, Europe, Asia, and RoW for 2010, 2011, 2012, and forecast for 2017
Radiopharmaceutical market for South Africa & Brazil
  • Market size estimation for South Africa and Brazil for 2010, 2011, 2012, and forecast for 2017
  • Regulatory affairs pertaining to Radiopharmaceutical market in South Africa and Brazil
2. Difference between carrier added and non carrier added Lu-177 molecule
  • Various advantages and disadvantages of carrier added and non carrier added Lu-177 molecule
3. Switzerland Radiopharmaceuticals Market
  • Market size estimation of diagnostic and therapeutic radioisotopes in Switzerland for 2010, 2011, 2012, and forecast for 2017
  • Market size estimation of SPECT and PET isotopes for 2010, 2011, 2012, and forecast for 2017
  • Market size estimation of Beta emitters and Brachytherapy isotopes for 2010, 2011, 2012, and forecast for 2017
  • Regulatory affairs pertaining to Radiopharmaceutical market in Switzerland
  • Market share analysis of Swiss Radiopharmaceutical market
  • Customer Interested in this report also can view
  • North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
  • European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017
  • Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
1 INTRODUCTION

1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
  1.5.1 MARKET SIZE
  1.5.2 MARKET SHARE
  1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
  1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
  1.5.5 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW

3.1 DEFINITION OF RADIOPHARMACEUTICALS
3.2 EVOLUTION
3.3 MARKET SEGMENTATION
  3.3.1 RADIOPHARMACEUTICALS
  3.3.2 STABLE ISOTOPES
3.4 MARKET DYNAMICS
  3.4.1 DRIVERS
    3.4.1.1 Increasing incidence of cancer and cardiac ailments boosts the demand for radiopharmaceuticals 46
    3.4.1.2 Increasing use of SPECT and PET scans results in rise of radiopharmaceutical usage
    3.4.1.3 Rising awareness of radiopharmaceuticals to spur growth
    3.4.1.4 Ready availability of radiopharmaceuticals from cyclotrons to goad the growth
  3.4.2 RESTRAINTS
    3.4.2.1 Shorter half-life of radiopharmaceuticals restricts its usage
    3.4.2.2 High capital to limit the buying of scanners
    3.4.2.3 Stringent regulatory guidelines and GMP to negatively impact growth
    3.4.2.4 Competition from conventional diagnostic procedures
  3.4.3 OPPORTUNITIES
    3.4.3.1 Potential radioisotopes in the pipeline
    3.4.3.2 High demand in emerging countries
    3.4.3.3 Alpha radio immunotherapy-based targeted cancer treatment
    3.4.3.4 Alternative diagnostic radiopharmaceutical solutions
    3.4.3.5 Cyclotron based production
    3.4.3.6 Neurological applications
  3.4.4 THREAT
    3.4.4.1 Shutdown of nuclear reactors to impact production of radioisotopes
3.5 WINNING IMPERATIVES
  3.5.1 INVESTMENTS ON NEW RADIOISOTOPES AND NOVEL APPLICATIONS
  3.5.2 SHIFT TOWARDS LEU-BASED MO-99 PRODUCTION
3.6 BURNING ISSUES
  3.6.1 HIGH COST OF PET CAMERAS
  3.6.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M
3.7 MARKET SHARE ANALYSIS
  3.7.1 RADIOPHARMACEUTICALS MARKET
  3.7.2 ENRICHED STABLE ISOTOPES MARKET
3.8 VALUE CHAIN ANALYSIS
  3.8.1 SPECT (MOLYBDENUM-99/TECHNETIUM-99M)
    3.8.1.1 Pricing structure in different phases of the value chain
    3.8.1.2 Cost modeling – LEU based Tc-99m production
  3.8.2 PET (FLUORINE-18)
  3.8.3 STABLE ISOTOPE (DEUTERIUM)
3.9 PIPELINE ANALYSIS
  3.9.1 DIAGNOSTIC RADIOISOTOPES
  3.9.2 THERAPEUTIC RADIOISOTOPES
3.10 DEMAND & SUPPLY ANALYSIS
  3.10.1 DEMAND FOR MO-99/TC-99M
    3.10.1.1 Availability of SPECT cameras to stabilize demand
    3.10.1.2 Stringent regulatory and reimbursement procedures for alternative isotopes prevents shift from Tc-99
    3.10.1.3 Emerging markets will enhance usage of Tc-99m
    3.10.1.4 Potential growth of Tc-99m based diagnostic imaging
    3.10.1.5 Shift from SPECT to PET
  3.10.2 CURRENT STATUS OF MO-99 SUPPLY
3.11 STRATEGIC BENCHMARKING
  3.11.1 PROCESSORS’ SHIFT FROM HEU TO LEU BASEDMO-99
    3.11.1.1 Contract extension by Nordion with AECL & supply agreement with RIAR
    3.11.1.2 Agreement of Covidien & IAE POLATOM with Maria reactor
    3.11.1.3 Agreement of NTP Radioisotopes with Lantheus Medical Imaging
  3.11.2 SUSTAINABLE SUPPLY CHAIN BY GENERATORS
    3.11.2.1 Contract extension of Lantheus Medical Imaging Inc., with NTP Radioisotopes (Pty) Ltd.
    3.11.2.2 Extension of contract & acquisition by IBA Group
    3.11.2.3 Acquisition of CNS Therapeutics, Inc., by Covidien, Plc.
    3.11.2.4 Collaboration of NTP Radioisotopes Pty Ltd. with ANSTO
    3.11.2.5 Expansion and agreement of FujiFilm Holdings Corporation
3.12 REGULATORY AFFAIRS
  3.12.1 GUIDELINES IN THE U.S.
  3.12.2 GUIDELINES IN EUROPE
  3.12.3 REIMBURSEMENT
  3.12.4 SAFETY OF PERSONNEL
  3.12.5 WASTE DISPOSAL
  3.12.6 EQUIPMENT & FACILITY
  3.12.7 TRANSPORTATION GUIDELINES

4 GLOBAL RADIOPHARMACEUTICALS MARKET, BY VALUE

4.1 INTRODUCTION
4.2 DIAGNOSTIC MARKET
  4.2.1 OPPORTUNITY MATRIX
  4.2.2 SPECT RADIOPHARMACEUTICALS
    4.2.2.1 Technetium-99m (Tc-99m)
      4.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes
      4.2.2.1.2 Factors affecting Technetium-99m market
        4.2.2.1.2.1 Technetium can combine with 31 different carrier molecules
        4.2.2.1.2.2 Lack of availability of technetium
    4.2.2.2 Thallium-201 (Tl-201)
      4.2.2.2.1 Tl-201 is a potential substitute for Tc-99m
    4.2.2.3 Gallium-67 (Ga-67)
      4.2.2.3.1 Fluorine-18 might seize Ga-67 market share in the near future
    4.2.2.4 Iodine (I-123)
    4.2.2.5 Others
  4.2.3 PET RADIOPHARMACEUTICALS
    4.2.3.1 Fluorine-18
      4.2.3.1.1 FDG
      4.2.3.1.2 Florbetapir
      4.2.3.1.3 Factors affecting Fluorine-18 market
        4.2.3.1.3.1 Increasing availability of PET machines
        4.2.3.1.3.2 Rise in PET procedures increases demand for FDG
        4.2.3.1.3.3 High generation costs of FDG
        4.2.3.1.3.4 Need for speedy & efficient transportation
    4.2.3.2 Rubidium-82 (Rb-82)
      4.2.3.2.1 Bracco re-launched CardioGen-82 in February 2012
    4.2.3.3 Others
      4.2.3.3.1 Ga-68 deemed as a potential PET radioisotope
4.3 THERAPEUTIC MARKET
  4.3.1 OPPORTUNITY MATRIX
  4.3.2 BETA EMITTERS
    4.3.2.1 Iodine-131 (I-131)
    4.3.2.2 Yttrium-90 (Y-90)
      4.3.2.2.1 Y-90 market influenced by popularity of Nordion’s TheraSphere
    4.3.2.3 Samarium-153 (Sm-153)
    4.3.2.4 Rhenium-186 (Re-186)
    4.3.2.5 Lutetium-177 (Lu-177)
      4.3.2.5.1 Lu-177 is a potential treatment option for neuroendocrine cancer
    4.3.2.6 Others
      4.3.2.6.1 Re-188 and P-33 are notable promising isotope
  4.3.3 ALPHA EMITTERS
    4.3.3.1 Radium-223 (Ra-223) & Alpharadin
      4.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC
      4.3.3.1.2 First in-class alpha pharmaceutical
      4.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy
      4.3.3.1.4 Success of Alpharadin
      4.3.3.1.5 Porter’s five forces analysis
      4.3.3.1.6 Alpharadin market potential post launch
      4.3.3.1.7 SWOT Analysis
    4.3.3.2 Actinium-225 (Ac-225)
    4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212)
    4.3.3.4 Astatine-211 (At-211)
    4.3.3.5 Radium-224 (Ra-224)
    4.3.3.6 Thorium-227 (Th-227)
  4.3.4 BRACHYTHERAPY
    4.3.4.1 U.S. to show slow growth due to reimbursement issues
    4.3.4.2 Cesium-131
    4.3.4.3 Iodine-125
    4.3.4.4 Palladium-103
    4.3.4.5 Iridium-192
    4.3.4.6 Others

5 GLOBAL RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

5.1 INTRODUCTION
  5.1.1 HOSPITAL BASED & LOCAL REACTORS GENERATED ISOTOPES TO BOOST THE PROCEDURAL MARKET
5.2 DIAGNOSTIC MARKET
  5.2.1 SPECT RADIOPHARMACEUTICALS
  5.2.2 PET RADIOPHARMACEUTICALS
5.3 THERAPEUTIC MARKET
  5.3.1 BETA EMITTERS
  5.3.2 BRACHYTHERAPY

6 RADIOPHARMACEUTICALS MARKET, BY APPLICATION/INDICATION

6.1 INTRODUCTION
6.2 DIAGNOSTIC MARKET
  6.2.1 SPECT
    6.2.1.1 Cardiology
    6.2.1.2 Lymphoma
    6.2.1.3 Thyroid
    6.2.1.4 Neurology
      6.2.1.4.1 Alzheimer’s, dementia, and Parkinson’s disease drives growth of the neurology SPECT market
    6.2.1.5 Others
  6.2.2 PET APPLICATION
    6.2.2.1 Oncology
      6.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan
    6.2.2.2 Cardiology
    6.2.2.3 Neurology
      6.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 dopa) are potential substitutes of FDG F-18
    6.2.2.4 Others
6.3 THERAPEUTIC APPLICATION
  6.3.1 THYROID
  6.3.2 BONE METASTASIS
  6.3.3 LYMPHOMA
    6.3.3.1 Novel clinical studies goading lymphoma therapy market
  6.3.4 ENDOCRINE TUMORS
  6.3.5 OTHERS

7 ENRICHED STABLE ISOTOPES MARKET

7.1 INTRODUCTION
7.2 MARKET OVERVIEW
  7.2.1 ASIA ACCOUNTS FOR THE LARGEST MARKET SHARE
7.3 MARKET DYNAMICS
  7.3.1 DRIVERS
    7.3.1.1 Stable isotopes are natural in origin & hence safe
    7.3.1.2 Proteomics & system biology, major factors to boost the growth of stables
    7.3.1.3 Medical applications propel stable isotopes market growth
  7.3.2 RESTRAINTS
    7.3.2.1 Harmful effects of stable isotopes affect market growth
    7.3.2.2 High cost of stables isotope
7.4 ENRICHED STABLES MARKET, BY ISOTOPES
  7.4.1 DEUTERIUM & O-18 ARE PROMISING ISOTOPES
  7.4.2 CARBON-13
  7.4.3 DEUTERIUM
  7.4.4 OXYGEN-18
  7.4.5 NITROGEN-15
  7.4.6 OTHER STABLE ISOTOPES
7.5 ENRICHED STABLES MARKET, BY APPLICATIONS
  7.5.1 DIAGNOSTIC & THERAPEUTIC
  7.5.2 RESEARCH
  7.5.3 PHARMACEUTICALS
  7.5.4 INDUSTRIAL SECTOR

8 GEOGRAPHIC ANALYSIS

8.1 INTRODUCTION
8.2 DIAGNOSTIC MARKET
  8.2.1 NORTH AMERICA
    8.2.1.1 Increasing adoption of alternative production technologies to make up for the shortage of Mo-99
  8.2.2 EUROPE
    8.2.2.1 SPECT and PET contributes almost equal in Europe
    8.2.2.2 Stringent regulations hindering market growth
  8.2.3 ASIA
    8.2.3.1 Asia promises the highest CAGR in the forecast period
  8.2.4 REST OF THE WORLD (ROW)
8.3 THERAPY MARKET
  8.3.1 NORTH AMERICA
    8.3.1.1 Nuclear medicine research drives the beta emitters market
  8.3.2 EUROPE
  8.3.3 ASIA
  8.3.4 REST OF THE WORLD (ROW)
8.4 ENRICHED STABLE ISOTOPES MARKET
  8.4.1 ASIA
  8.4.2 NORTH AMERICA
  8.4.3 EUROPE
  8.4.4 REST OF THE WORLD (ROW)

9 COMPETITIVE LANDSCAPE

9.1 INTRODUCTION
9.2 MERGERS & ACQUISITIONS
9.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
9.4 PRODUCTS LAUNCH
9.5 EXPANSIONS
9.6 OTHER DEVELOPMENTS
9.7 APPROVALS

10 COMPANY PROFILES(Overview, Financials, Products & Services, Strategy, & Developments)

10.1 COMPANIES
  10.1.1 BRACCO IMAGING S.P.A.
  10.1.2 CAMBRIDGE ISOTOPE LABORATORIES, INC.
  10.1.3 CARDINAL HEALTH, INC.
  10.1.4 COVIDIEN, PLC
  10.1.5 ECZACIBASI-MONROL
  10.1.6 FUJIFILM HOLDINGS CORPORATION
  10.1.7 GE HEALTHCARE (SUBSIDIARY OF GENERAL ELECTRIC COMPANY)
  10.1.8 IBA GROUP
  10.1.9 ISOTEC, INC. (SIGMA-ALDRICH)
  10.1.10 LANTHEUS MEDICAL IMAGING, INC.
  10.1.11 NORDION, INC.
  10.1.12 NTP RADIOISOTOPES (PTY), LTD.
  10.1.13 PETNET SOLUTIONS, INC. (A SUBSIDIARY OF SIEMENS MEDICAL SOLUTIONS USA, INC.)
  10.1.14 TAIYO NIPPON SANSO CORPORATION
  10.1.15 URENCO LIMITED
  10.1.16 ROTEM INDUSTRIES, LTD., INC.
10.2 INSTITUTES
  10.2.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO)
  10.2.2 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT)
  10.2.3 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE
  10.2.4 INSTITUTE OF ISOTOPES CO., LTD.
  10.2.5 INSTITUTE OF RADIOELEMENT (IRE)(Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)

LIST OF TABLES

TABLE 1 RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 2 COST INCREASE OF TC-99M: PHASES OF SUPPLY CHAIN (%)
TABLE 3 COST RANGE: NEW & MODIFIED RIG ($MILLION)
TABLE 4 COST RANGE: NEW & MODIFIED CONTAINERS ($MILLION)
TABLE 5 COST INCREASE FOR LEU-BASED CONVERSION (%)
TABLE 6 COST IMPACT: PHASES OF SUPPLY CHAIN ($/6-DAY CURIE)
TABLE 7 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS, 2010 – 2017
TABLE 8 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS, 2010 – 2017
TABLE 9 MO-99: WEEKLY DEMAND (2011)
TABLE 10 MO-99: PRODUCTION PER WEEK (2010)
TABLE 11 TC-99M: PROCESSING CAPACITY (2011)
TABLE 12 MO-99: POTENTIAL REACTORS
TABLE 13 GLOBAL RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 14 GLOBAL SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 15 SPECT RADIOPHARMACEUTICAL MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 16 INDICATIONS DIAGNOSED BY TC-99M
TABLE 17 TC-99M MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 18 TL-201 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 19 GA-67 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 20 I-123 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 21 OTHER RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 22 PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 23 GLOBAL PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 24 F-18 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 25 RB-82 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 26 OTHER PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 27 GLOBAL BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 28 BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 29 I-131 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 30 Y-90 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 31 SM-153 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 32 RE-186 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 33 LU-177 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 34 OTHER BETA-EMITTER RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 35 ALPHA EMITTERS VS BETA EMITTERS
TABLE 36 HRPCA BONE METASTASIS THERAPY MARKET & ALPHARADIN ADDRESSABLE MARKET, 2015 ($MILLION)
TABLE 37 RADIOISOTOPE CHARACTERISTICS & DOSE DELIVERY OVER TIME
TABLE 38 GLOBAL BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 39 BRACHYTHERAPY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 40 CS-131 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 41 I-125 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 42 PD-103 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 43 IR-192 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 44 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 45 RADIOPHARMACEUTICAL PROCEDURES MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION)
TABLE 46 GLOBAL DIAGNOSTIC RADIOPHARMACEUTICAL PROCEDURES MARKET, BY TECHNOLOGY, 2010 – 2017 (MILLION)
TABLE 47 GLOBAL SPECT RADIOPHARMACEUTICAL PROCEDURES MARKET, BY ISOTOPE, 2010 – 2017 (MILLION)
TABLE 48 SPECT RADIOPHARMACEUTICAL PROCEDURES MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION)
TABLE 49 GLOBAL PET RADIOPHARMACEUTICAL PROCEDURES MARKET, BY ISOTOPE, 2010 – 2017 (MILLION)
TABLE 50 PET RADIOPHARMACEUTICAL PROCEDURES MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION)
TABLE 51 GLOBAL THERAPEUTIC RADIOPHARMACEUTICAL PROCEDURES MARKET, BY TYPE, 2010 – 2017 (MILLION)
TABLE 52 GLOBAL BETA EMITTER PROCEDURES MARKET, BY ISOTOPE, 2010 – 2017 (MILLION)
TABLE 53 BETA EMITTERS RADIOPHARMACEUTICAL PROCEDURES MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION)
TABLE 54 GLOBAL BRACHYTHERAPY PROCEDURES MARKET, BY ISOTOPE, 2010 – 2017 (MILLION)
TABLE 55 BRACHYTHERAPY RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION)
TABLE 56 SPECT APPLICATION MARKET, 2010 – 2017 ($MILLION)
TABLE 57 CARDIOLOGY SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 58 LYMPHOMA SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 59 THYROID SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 60 NEUROLOGY SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 61 OTHER SPECT APPLICATIONS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 62 GLOBAL PET APPLICATION MARKET, 2010 – 2017 ($MILLION)
TABLE 63 ONCOLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 64 CARDIOLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 65 NEUROLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 66 OTHER PET APPLICATIONS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 67 GLOBAL RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC APPLICATIONS,2010 – 2017 ($MILLION)
TABLE 68 RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC APPLICATIONS, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 69 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR THYROID APPLICATION, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 70 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR BONE METASTASIS APPLICATION, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 71 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR LYMPHOMA APPLICATION, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 72 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR ENDOCRINE APPLICATION, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 73 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 74 GLOBAL STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION)
TABLE 75 STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 76 CARBON STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 77 DEUTERIUM STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 78 OXYGEN STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 79 NITROGEN STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 80 OTHER STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 81 GLOBAL ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION, 2010 – 2017 ($MILLION)
TABLE 82 STABLE ISOTOPES MARKET FOR MEDICAL APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 83 STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 84 STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 85 STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 86 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 87 SPECT RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 88 PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 89 NORTH AMERICA: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 90 NORTH AMERICA: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 91 NORTH AMERICA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 92 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 93 EUROPE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 94 EUROPE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 95 ASIA: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 96 ASIA: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 97 ASIA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 98 ROW: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 99 ROW: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 100 ROW: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 101 BETA EMITTER MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 102 BRACHYTHERAPY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 103 NORTH AMERICA: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION)
TABLE 104 NORTH AMERICA: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 105 NORTH AMERICA: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 106 EUROPE: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION)
TABLE 107 EUROPE: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 108 EUROPE: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 109 ASIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION)
TABLE 110 ASIA: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 111 ASIA: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 112 ROW: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION)
TABLE 113 ROW: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 114 ROW: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION)
TABLE 115 ENRICHED STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 116 ASIA: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION)
TABLE 117 ASIA: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION, 2010 – 2017 ($MILLION)
TABLE 118 NORTH AMERICA: ENRICHED STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION)
TABLE 119 NORTH AMERICA: STABLE ISOTOPE MARKET, BY APPLICATION, 2010 – 2017 ($MILLION)
TABLE 120 EUROPE: ENRICHED STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION)
TABLE 121 EUROPE: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION, 2010 – 2017 ($MILLION)
TABLE 122 ROW: ENRICHED STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION)
TABLE 123 ROW: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION, 2010 – 2017 ($MILLION)
TABLE 124 MERGERS & ACQUISITIONS, 2010 – 2012
TABLE 125 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013
TABLE 126 PRODUCTS LAUNCH, 2010 – 2013
TABLE 127 EXPANSIONS, 2010 – 2012
TABLE 128 OTHER DEVELOPMENTS, 2010 – 2012
TABLE 129 APPROVALS, 2010 – 2011
TABLE 130 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 131 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 132 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 133 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 134 COVIDIEN, PLC: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 135 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 136 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 137 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 138 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 139 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION)
TABLE 140 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($BILLION)
TABLE 141 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($BILLION)
TABLE 142 IBA GROUP: MARKET REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 143 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 144 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 145 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 146 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 147 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 148 NORDION, INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 149 NORDION, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 150 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 151 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 152 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 153 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)

LIST OF FIGURES

FIGURE 1 GLOBAL RADIOPHARMACEUTICAL MARKET, BY SEGMENT, 2010 – 2017
FIGURE 2 RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2012 ($MILLION)
FIGURE 3 GLOBAL STABLE ISOTOPES MARKET, 2012 – 2017 ($MILLION)
FIGURE 4 EVOLUTION OF RADIOPHARMACEUTICALS
FIGURE 5 RADIOPHARMACEUTICALS MARKET SEGMENTATION
FIGURE 6 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 RADIOPHARMACEUTICALS: MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012
FIGURE 9 ENRICHED STABLE ISOTOPE: MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012
FIGURE 10 MO-99/TC-99M: SUPPLY CHAIN
FIGURE 11 TC-99M: SUPPLY CHAIN PARTICIPANTS
FIGURE 12 TC-99M: VALUE CHAIN ANALYSIS
FIGURE 13 TC-99M: PRICING FACTORS
FIGURE 14 FLUORINE-18: SUPPLY CHAIN
FIGURE 15 DEUTERIUM: SUPPLY CHAIN
FIGURE 16 MAJOR SPONSORS, CLINICAL STUDIES, 2010 – 2017
FIGURE 17 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC APPLICATIONS OF RADIOISOTOPES, BY PHASE, 2010 – 2017
FIGURE 18 CLINICAL TRIALS (PHASE III & IV) FOR DIAGNOSTIC RADIOISOTOPES, 2010 – 2017
FIGURE 19 UPCOMING RADIOPHARMACEUTICAL APPLICATIONS (DIAGNOSIS), 2010 – 2017
FIGURE 20 CLINICAL TRIALS (PHASE III & IV) FOR THERAPEUTIC RADIOISOTOPES, 2010 – 2017
FIGURE 21 UPCOMING RADIOPHARMACEUTICAL APPLICATIONS (THERAPY), 2010 – 2017
FIGURE 22 MO-99 DEMAND (SIX DAYS CURIE) PER WEEK, 2012 VS 2030
FIGURE 23 MO-99: SUPPLY VS DEMAND ANALYSIS, 2010 – 2020
FIGURE 24 SHIFT TOWARDS LEU FROM HEU
FIGURE 25 SUSTAINABLE SUPPLY CHAIN & LOGISTICS
FIGURE 26 OPPORTUNITY MATRIX: GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET (2012)
FIGURE 27 SPECT RADIOISOTOPE MARKET SHARE (2012)
FIGURE 28 PET RADIOPHARMACEUTICALS MARKET SHARE (2012)
FIGURE 29 OPPORTUNITY MATRIX: GLOBAL THERAPEUTIC RADIOPHARMACEUTICALS MARKET (2012)
FIGURE 30 RA-223 DECAY CHAIN
FIGURE 31 PORTER’S FIVE FORCES ANALYSIS FOR ALPHARADIN
FIGURE 32 SWOT ANALYSIS OF ALPHARADIN
FIGURE 33 GLOBAL RADIOPHARMACEUTICAL PROCEDURES MARKET, 2012
FIGURE 34 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY INDICATION (2012)
FIGURE 35 KEY GROWTH STRATEGIES, 2010 – 2013
FIGURE 36 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
FIGURE 37 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 – 2012 ($BILLION)
FIGURE 38 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE, 2010 – 2012 ($MILLION)
FIGURE 39 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION)
FIGURE 40 IBA GROUP: TOTAL MARKET REVENUE, 2009 – 2011 ($MILLION)
FIGURE 41 ISOTEC INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION)
FIGURE 42 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 43 NORDION, INC.: TOTAL MARKET REVENUE, 2010 – 2012 ($MILLION)
FIGURE 44 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION)
FIGURE 45 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 – 2011 ($BILLION)

Ask Your Question

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: